Course Overview
Program Overview
Adult-onset growth hormone deficiency (AGHD) is an often underrecognized disorder that can significantly affect patient health and quality of life. This symposium will review early signs and symptoms of AGHD and help clinicians identify patients who may benefit from diagnostic screening. Faculty will discuss biochemical testing strategies, including interpretation based on age, gender, and other patient-specific factors, as well as the role of common comorbidities in contributing to increased health risks.
The program will compare the safety and effectiveness of current and emerging treatment options and review key findings from recent Phase III clinical trials. Practical strategies for individualized treatment planning and patient monitoring will also be explored to support optimal outcomes in diverse patient populations.
Program Agenda
Welcome and Introduction
– Maria Fleseriu, MD, FACE
GHD in Adults and Children – Delphi Panel Consensus
– Maya Lodish, MD, MHSc
Short- and Long-Term Outcomes in Patients Treated with GH for GHD – Case Presentations
– Roberto Salvatori, MD
Long-Acting GH in Adults – Clinical Trials, Monitoring and Controversies
– Katharina Schilbach, MD
Panel Discussion and Questions
– Faculty Panel
Upon completion of this educational activity, participants should be able to:
Identify early signs of adult-onset growth hormone (GH) deficiency and determine which patients may benefit from diagnostic screening
Explain biochemical testing strategies for diagnosing adult GH deficiency, including the impact of age, gender, and other patient-specific factors on test interpretation
Recognize common comorbid conditions associated with adult GH deficiency and understand their potential contribution to increased mortality risk
Evaluate the safety and effectiveness of current and emerging treatment options for adult GH deficiency
Interpret key findings from recent Phase III clinical trials related to adult GH deficiency findings
Physician Continuing Medical Education
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Your CE Source and CMM Global. Your CE Source is accredited by the ACCME to provide continuing medical education for physicians.
Your CE Source designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
Your CE Source is an approved provider of continuing nursing education by the California Board of Registered Nursing. Provider approved by California Board of Registered Nursing, Provider #16031 for 1.25 contact hours.
Program Faculty
Program Chair
Maria Fleseriu, MD
Professor of Medicine and Neurological Surgery
Director, Pituitary Center
Oregon Health & Science University
Portland, USA
Faculty Disclosure: research support for GHD from Ascendis to the University as Principal Investigator and scientific consultancy honorarium from Novo Nordisk
Faculty Presenter
Maya Lodish, MD, MHSc
Professor of Pediatric Endocrinology and Diabetes
University of California - San Francisco
San Francisco, CA, USA
Faculty Disclosure: research support/lecture fees/honoraria/travel from Ascendis, Neurocrine, Pfizer and Recordati
Faculty Presenter
Roberto Salvatori, MD
Professor of Medicine,
Department of Endocrinology
Johns Hopkins Medical Center
Baltimore, MD, USA
Faculty Disclosure: consultant Camurus, Chiesi, Crinetics, Lundbeck and Debiopharm and clinical trials support from Novo Nordisk and Recordati
Faculty Presenter
Katharina Schilbach, MD
Consultant Endocrinologist
LMU Klinikum
Munich, Germany
Faculty Disclosure: research support/lecture fees/honoraria/travel from Ascendis, Novo Nordisk, Pfizer and Recordati
All other faculty, planner and/or content managers have nothing to disclose nor do they have any vested interests or affiliations.